KOGISO Tomomi    Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine    Position   Assistant Professor
Article types	Review article
Language	English
Peer review	Non peer reviewed
Title	Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?
Journal	Formal name：International journal of molecular sciences Abbreviation：Int J Mol Sci ISSN code：14220067/14220067
Domestic / Foregin	Foregin
Volume, Issue, Page	21(14),pp.4939
Author and coauthor	Sumida Yoshio, Yoneda Masashi, Toyoda Hidenori, Yasuda Satoshi, Tada Toshifumi, Hayashi Hideki, Nishigaki Yoichi, Suzuki Yusuke, Naiki Takafumi, Morishita Asahiro, Tobita Hiroshi, Sato Shuichi, Kawabe Naoto, Fukunishi Shinya, Ikegami Tadashi, Kessoku Takaomi, Ogawa Yuji, Honda Yasushi, Nakahara Takashi, Munekage Kensuke, Ochi Tsunehiro, Sawada Koji, Takahashi Atsushi, Arai Taeang, Kogiso Tomomi, Kimoto Satoshi, Tomita Kengo, Notsumata Kazuo, Nonaka Michihiro, Kawata Kazuhito, Takami Taro, Kumada Takashi, Tomita Eiichi, Okanoue Takeshi, Nakajima Atsushi, Japan Study Group Of Nafld Jsg-Nafld
Publication date	2020/07
Summary	Type 2 diabetes (T2D) is associated with diabetic nephropathy as well as nonalcoholic steatohepatitis (NASH), which can be called "diabetic hepatopathy or diabetic liver disease". NASH, a severe form of nonalcoholic fatty disease (NAFLD), can sometimes progress to cirrhosis, hepatocellular carcinoma and hepatic failure. T2D patients are at higher risk for liver-related mortality compared with the nondiabetic population. NAFLD is closely associated with chronic kidney disease (CKD) or diabetic nephropathy according to cross-sectional and longitudinal studies. Simultaneous kidney liver transplantation (SKLT) is dramatically increasing in the United States, because NASH-related cirrhosis often complicates end-stage renal disease. Growing evidence suggests that NAFLD and CKD share common pathogenetic mechanisms and potential therapeutic targets. Glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors are expected to ameliorate NASH and diabetic nephropathy/CKD. There are no approved therapies for NASH, but a variety of drug pipelines are now under development. Several agents of them can also ameliorate diabetic nephropathy/CKD, including peroxisome proliferator-activated receptors agonists, apoptosis signaling kinase 1 inhibitor, nuclear factor-erythroid-2-related factor 2 activator, C-C chemokine receptor types 2/5 antagonist and nonsteroidal mineral corticoid receptor antagonist. This review focuses on common drug pipelines in the treatment of diabetic nephropathy and hepatopathy.
DOI	10.3390/ijms21144939
PMID	32668632